FOLETTA MARK G 4

What Happened

• Mark G. Foletta, a director of DexCom, reported the sale of a total of 4,000 shares of DexCom common stock on June 15, 2026. The sales consisted of 3,801 shares at a weighted average price of $74.10 ($281,651) and 199 shares at a weighted average price of $74.82 ($14,889), for combined proceeds of about $296,540. These were dispositions (sales), not purchases or option exercises.

Key Details

• Transaction dates: June 15, 2026; Form 4 filed June 17, 2026 (appears timely for a Form 4 covering a June 15 trade).
• Prices: weighted averages shown of $74.10 (for 3,801 shares) and $74.82 (for 199 shares). Filing notes the 3,801-share block traded in multiple trades at $73.70–$74.685 (F2) and the 199-share block at $74.78–$75.55 (F4); the filing offers to provide per-trade details on request.
• Holdings after transaction: not specified in the provided excerpt of the filing.
• Notable footnotes:
  • F1/F3: The shares were held by The Foletta Family Trust DTD 1/30/2015; Mr. Foletta is a trustee and the sales were made pursuant to a 10b5-1 trading plan adopted March 13, 2026.
  • F2/F4: Multiple-trade execution and weighted-average pricing; reporting person will provide trade-level details on request.
  • F5 (separate): The filing also references unvested RSUs granted May 28, 2026 that vest the earlier of one year after grant or the 2027 annual meeting (not part of these sales).

Context

• These were open-market sales of trust-held shares executed under a pre-established 10b5-1 plan, which is a common mechanism directors use to sell shares on a preset schedule. Sales under a 10b5-1 plan typically indicate pre-planned disposals rather than ad hoc insider selling; the filing itself does not state motivations. This transaction does not involve option exercises, gifts, or company-awarded shares being sold as part of a cashless exercise.